CL2019003270A1 - Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína. - Google Patents
Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.Info
- Publication number
- CL2019003270A1 CL2019003270A1 CL2019003270A CL2019003270A CL2019003270A1 CL 2019003270 A1 CL2019003270 A1 CL 2019003270A1 CL 2019003270 A CL2019003270 A CL 2019003270A CL 2019003270 A CL2019003270 A CL 2019003270A CL 2019003270 A1 CL2019003270 A1 CL 2019003270A1
- Authority
- CL
- Chile
- Prior art keywords
- carboxamides
- bis
- octahydrophenanthrene
- protein conjugates
- conjugates
- Prior art date
Links
- 150000003857 carboxamides Chemical class 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the nitrogen atom of at least one of the carboxamide groups further acylated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
EN EL PRESENTE DOCUMENTO SE PROPORCIONAN COMPUESTOS, COMPOSICIONES Y MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS ASOCIADOS CON EL RECEPTOR X DEL HÍGADO, INCLUIDAS LAS BIS-OCTAHIDROFENANTRENO CARBOXAMIDAS Y SUS CONJUGADOS DE PROTEÍNAS (POR EJEMPLO, ANTICUERPOS).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762508327P | 2017-05-18 | 2017-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019003270A1 true CL2019003270A1 (es) | 2020-05-08 |
Family
ID=62245504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019003270A CL2019003270A1 (es) | 2017-05-18 | 2019-11-14 | Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína. |
Country Status (16)
Country | Link |
---|---|
US (2) | US20180334426A1 (es) |
EP (1) | EP3625209A1 (es) |
JP (2) | JP2020520926A (es) |
KR (1) | KR20200008579A (es) |
CN (1) | CN111065622A (es) |
AU (1) | AU2018269568B2 (es) |
BR (1) | BR112019023990A2 (es) |
CA (1) | CA3063872A1 (es) |
CL (1) | CL2019003270A1 (es) |
CO (1) | CO2019014286A2 (es) |
EA (1) | EA201900562A1 (es) |
IL (1) | IL270595B2 (es) |
MA (1) | MA47392B1 (es) |
MX (1) | MX2019013693A (es) |
PH (1) | PH12019502576A1 (es) |
WO (1) | WO2018213082A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10202104259RA (en) | 2016-11-08 | 2021-06-29 | Regeneron Pharma | Steroids and protein-conjugates thereof |
KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
MX2020004691A (es) * | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
SG11202010909RA (en) | 2018-05-09 | 2020-12-30 | Regeneron Pharma | Anti-msr1 antibodies and methods of use thereof |
BR112021009673A2 (pt) | 2018-11-20 | 2021-12-14 | Regeneron Pharma | Derivados de bis-octa-hidrofenantreno carboxamida e conjugados de proteínas dos mesmos para uso como agonistas de lxr |
AU2020205662A1 (en) * | 2019-01-08 | 2021-07-22 | Regeneron Pharmaceuticals, Inc. | Traceless linkers and protein-conjugates thereof |
CN115968304A (zh) | 2020-04-16 | 2023-04-14 | 瑞泽恩制药公司 | 狄尔斯-阿尔德缀合方法 |
EP4172141A1 (en) * | 2020-06-26 | 2023-05-03 | Synaffix B.V. | Methods for the preparation of linker payload constructs |
CN116615257A (zh) | 2020-11-10 | 2023-08-18 | 瑞泽恩制药公司 | 硒抗体缀合物 |
CN112661783B (zh) * | 2020-12-28 | 2022-06-07 | 中国林业科学研究院林产化学工业研究所 | 一种硅氧烷二元松香基苯并环丁烯单体及其制备方法和应用 |
CN115006390B (zh) * | 2022-06-27 | 2024-04-19 | 国药集团动物保健股份有限公司 | 一种病毒减毒制剂、其制备方法以及应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
AU2064701A (en) * | 1999-12-13 | 2001-06-18 | Merck & Co., Inc. | Method for the prevention and/or treatment of atherosclerosis |
US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
US6908934B2 (en) * | 2001-06-11 | 2005-06-21 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
JP2008503229A (ja) * | 2004-06-24 | 2008-02-07 | ガラパゴス・ナムローゼ・フェンノートシャップ | 骨ホメオスタシスを促進させる方法及び組成物 |
US7238791B1 (en) * | 2005-12-16 | 2007-07-03 | Roche Diagnostics Operations, Inc. | 6-monoacetylmorphine derivatives useful in immunoassay |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
CA2687178C (en) | 2007-05-23 | 2014-02-04 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
CN104258413A (zh) | 2008-04-30 | 2015-01-07 | 伊缪诺金公司 | 有效的偶联物和亲水性连接体 |
EP2662095A1 (en) | 2010-04-15 | 2013-11-13 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
US9238690B2 (en) | 2010-10-29 | 2016-01-19 | Immunogen, Inc. | Non-antagonistic EGFR-binding molecules and immunoconjugates thereof |
MX371526B (es) | 2011-05-27 | 2020-01-31 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
KR101961976B1 (ko) | 2011-10-14 | 2019-03-25 | 시애틀 지네틱스, 인크. | 피롤로벤조디아제핀 및 표적 접합체 |
CN108164551A (zh) | 2011-10-14 | 2018-06-15 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
US9102704B2 (en) | 2011-10-14 | 2015-08-11 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
SI3912642T1 (sl) | 2012-10-23 | 2023-09-29 | Synaffix B. V. | Modificirano protitelo, konjugat protitelesa in postopek za pripravo le-teh |
JP6637415B2 (ja) * | 2013-10-15 | 2020-01-29 | ザ スクリプス リサーチ インスティテュート | キメラ抗原受容体t細胞スイッチおよびその使用 |
US10588980B2 (en) * | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
US20160324981A1 (en) * | 2015-05-08 | 2016-11-10 | The California Institute For Biomedical Research | Liver x receptor agonists and uses thereof |
US11786603B2 (en) | 2016-02-26 | 2023-10-17 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
SG11202010909RA (en) * | 2018-05-09 | 2020-12-30 | Regeneron Pharma | Anti-msr1 antibodies and methods of use thereof |
-
2018
- 2018-05-09 CA CA3063872A patent/CA3063872A1/en active Pending
- 2018-05-09 IL IL270595A patent/IL270595B2/en unknown
- 2018-05-09 KR KR1020197036866A patent/KR20200008579A/ko not_active Application Discontinuation
- 2018-05-09 US US15/975,654 patent/US20180334426A1/en not_active Abandoned
- 2018-05-09 AU AU2018269568A patent/AU2018269568B2/en active Active
- 2018-05-09 CN CN201880047919.2A patent/CN111065622A/zh active Pending
- 2018-05-09 EP EP18727582.1A patent/EP3625209A1/en active Pending
- 2018-05-09 EA EA201900562A patent/EA201900562A1/ru unknown
- 2018-05-09 BR BR112019023990-1A patent/BR112019023990A2/pt unknown
- 2018-05-09 MX MX2019013693A patent/MX2019013693A/es unknown
- 2018-05-09 WO PCT/US2018/031910 patent/WO2018213082A1/en unknown
- 2018-05-09 MA MA47392A patent/MA47392B1/fr unknown
- 2018-05-09 JP JP2019563612A patent/JP2020520926A/ja active Pending
-
2019
- 2019-11-14 CL CL2019003270A patent/CL2019003270A1/es unknown
- 2019-11-18 PH PH12019502576A patent/PH12019502576A1/en unknown
- 2019-12-17 CO CONC2019/0014286A patent/CO2019014286A2/es unknown
-
2021
- 2021-10-05 US US17/494,762 patent/US20220112158A1/en active Pending
-
2023
- 2023-05-09 JP JP2023077334A patent/JP2023113639A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN111065622A (zh) | 2020-04-24 |
CO2019014286A2 (es) | 2020-04-01 |
IL270595B1 (en) | 2023-05-01 |
PH12019502576A1 (en) | 2020-09-28 |
MA47392B1 (fr) | 2021-09-30 |
US20180334426A1 (en) | 2018-11-22 |
IL270595A (es) | 2019-12-31 |
CA3063872A1 (en) | 2018-11-22 |
IL270595B2 (en) | 2023-09-01 |
JP2023113639A (ja) | 2023-08-16 |
JP2020520926A (ja) | 2020-07-16 |
WO2018213082A1 (en) | 2018-11-22 |
MX2019013693A (es) | 2020-01-27 |
KR20200008579A (ko) | 2020-01-28 |
MA47392A1 (fr) | 2020-10-28 |
AU2018269568B2 (en) | 2022-03-24 |
BR112019023990A2 (pt) | 2020-06-16 |
EP3625209A1 (en) | 2020-03-25 |
US20220112158A1 (en) | 2022-04-14 |
AU2018269568A1 (en) | 2020-01-16 |
EA201900562A1 (ru) | 2020-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019003270A1 (es) | Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína. | |
CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
ECSP18094857A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
CL2017001289A1 (es) | Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). | |
EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
CO2018012946A2 (es) | Moduladores de la vía de estrés integrada | |
EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
CL2017000806A1 (es) | Compuestos anti-tnf | |
CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
CO2018001840A2 (es) | Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5 | |
ECSP17038999A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
CU20170018A7 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo | |
CL2018000597A1 (es) | Métodos para tratar enfermedades inflamatorias | |
CL2021001593A1 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
CL2017001310A1 (es) | Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis | |
BR112018070497A2 (pt) | métodos e formulações farmacêuticas para tratamento de condições oculares | |
CL2017000087A1 (es) | Un proceso novedoso para la purificación de rhu-gcsf | |
CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
EA201790893A1 (ru) | Способы лечения офтальмологических расстройств | |
EA201692482A1 (ru) | Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) | |
CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. |